Cogent Biosciences, Inc. - COGT STOCK NEWS

Cogent Biosciences (Nasdaq: COGT) appointed Evan Kearns as Chief Legal Officer on May 3, 2021. Kearns brings nearly 15 years of biopharmaceutical experience, previously serving at Agenus Inc. and Goodwin Procter LLP. He will oversee legal operations as the company prepares to initiate multiple clinical studies of CGT9486 this year, targeting genetically-driven diseases. Cogent is on track to commence three late-stage clinical trials in 2021, supported by a robust cash position, enabling the expansion of its research pipeline.

Cogent Biosciences (Nasdaq: COGT) announced the formation of the Cogent Research Team, spearheaded by new Chief Scientific Officer John Robinson, PhD. The team will focus on developing small molecule therapies for rare, genetically driven diseases. Robinson brings over 15 years of experience, having previously led teams at Pfizer and Array BioPharma. The company is set to initiate three late-stage clinical trials for its lead program, CGT9486, in 2021, supported by strong cash reserves into 2024.

Cogent Biosciences (Nasdaq: COGT) reported its financial results for Q4 2020, showing a net loss of $11.3 million, down from a net income of $2.3 million in Q4 2019. R&D expenses were $6.1 million for the quarter, while G&A expenses totaled $5.3 million. Despite these losses, Cogent had cash and equivalents of $242.2 million, sufficient to support operations through 2024. The company plans to initiate clinical trials for CGT9486 in systemic mastocytosis and GIST in 2021, supported by an upsized public offering that raised approximately $115 million.

Cogent Biosciences, Inc. (Nasdaq: COGT) announced the appointment of Todd E. Shegog to its Board of Directors, effective February 22, 2021. Shegog brings over 25 years of experience in finance and operations within the biotech sector, previously serving as CFO at Forma Therapeutics, Synlogic, and Millennium Pharmaceuticals. CEO Andrew Robbins expressed confidence in Shegog's ability to enhance the company’s financial strategies as it advances its lead program, CGT9486, into new clinical trials targeting systemic mastocytosis and GIST this year.

Cogent Biosciences will present at the 10th Annual SVB Leerlink Global Healthcare Conference on February 25, 2021, from 3:00-3:30 PM ET. CEO Andrew Robbins will lead the presentation. The event can be accessed via the investor relations section of their website, where a live webcast and archived recording will be available. Cogent specializes in developing precision therapies for genetically defined diseases, with its lead program, CGT9486, targeting the KIT D816V mutation related to systemic mastocytosis and gastrointestinal stromal tumors.

Cogent Biosciences (Nasdaq: COGT) announced that CEO Andrew Robbins will present a corporate overview at the LifeSci Partners Precision Oncology Day on February 17, 2021. The event will be held virtually, and a recording of the presentation will be accessible on Cogent's investor relations website after the event. The company focuses on developing precision therapies for genetically defined diseases, with its leading clinical program, CGT9486, addressing the KIT D816V mutation linked to systemic mastocytosis. For updates, follow Cogent on Twitter and LinkedIn.

Cogent Biosciences, Inc. (NASDAQ: COGT) has successfully closed an upsized public offering of 11,794,872 shares at $9.75 per share, raising approximately $108.1 million after costs. This includes the full exercise of the underwriters' option for an additional 1,538,461 shares. The proceeds are earmarked for the ongoing development and regulatory preparation of PLX9486, aimed at treating systemic mastocytosis and gastrointestinal stromal tumors (GIST). The offering was facilitated by Jefferies and Piper Sandler as joint book-running managers.

Cogent Biosciences, Inc. (Nasdaq: COGT) has announced the pricing of an underwritten public offering of 10,256,411 shares at $9.75 per share, up from an initial $60 million to approximately $100 million. The offering includes a 30-day option for underwriters to buy up to 1,538,461 additional shares. Proceeds will support development and regulatory activities for PLX9486 and other candidates, as well as general corporate purposes. The offering is expected to close around December 4, 2020.

Cogent Biosciences, a biotechnology company specializing in precision therapies for genetically defined diseases, has initiated a public offering of $60 million in common stock. Additionally, underwriters have a 30-day option to purchase up to $9 million more. The proceeds will support development and regulatory activities for PLX9486 and other candidates, along with general corporate expenses. Jefferies and Piper Sandler are leading the offering. The registration statement is effective, but these securities are not qualified under state laws.